Background
==========

A fundamental question in biology is how cells and tissues differentiate and maintain their identity from essentially the same genome. Wide variation in spatial, temporal and condition-dependent expression patterns of more than 20,000 genes in the human genome \[[@B1]\] is required for the establishment and maintenance of different cell fates and environmental responses. Tissue-specific genes are often implicated in distinct developmental and metabolic pathways and therefore may constitute good candidates for biomarkers or drug targets.

The control of gene transcription is mediated by transcription factors (TFs), which interact in a sequence-specific manner with DNA motifs, known as TF binding sites. The promoter is frequently divided into a basal core, covering approximately 100 bp upstream of the transcription start site (TSS), and a proximal promoter, which extends up to a few hundred base pairs and typically contains multiple TF binding sites \[[@B2],[@B3]\]. In addition to promoters, other *cis*-regulatory sequences, such as enhancers, are specifically bound by TFs and are central players in the control of transcription in multicellular eukaryotes. The regulation of promoters by distal enhancers involves DNA looping or scanning and/or higher-order conformation changes in chromatin \[[@B4]-[@B6]\], resulting in an increase in the local concentration of TFs in the vicinity of a promoter and the initiation or enhancement of transcription. It has been long recognized that proximal promoters and enhancers are functionally similar, and virtually undistinguishable from each other (see, for example, \[[@B7],[@B8]\]).

Both enhancers and promoters have been shown to contain DNA motifs for specific TFs, depending on their tissue-specific activities (for example, \[[@B8]-[@B10]\]). In particular, CpG-depleted promoters are enriched with DNA motifs \[[@B11]\], suggesting a distinct regulatory mechanism from CpG-rich promoters. The transcription complex LDB1, which involves GATA1, GATA2, TAL1, LMO2, and RUNX1, and has been extensively studied in the context of the differentiation of erythroid cells, illuminates this distinction. Whereas LDB1 binds mostly within CpG-depleted promoters, it only binds downstream of CpG-rich promoters, often within the first intron of their target gene \[[@B12]\]. Additional evidence suggests that such DNA motifs representing putative TF binding sites are predictive of promoter activity, including tissue-specific expression of their target gene (for example, \[[@B13],[@B14]\]). In addition, DNA motif enrichment analyses have shown that DNA motifs are highly predictive of enhancer activity \[[@B15]-[@B18]\].

Unlike promoters, enhancers can act over very long distances. Based on the relative location of conserved non-coding elements (CNEs) in the human genome, early estimates suggested that a large number of enhancers are more than 250 kilobases (kb) away from their target gene \[[@B19]\]. For example, a conserved enhancer of *Shh* that is associated with polydactyly is located 1 megabase (Mb) upstream of *Shh*, within an intron of another gene \[[@B20]\]. Furthermore, similar approaches have determined that the regulatory elements controlling the transcription of SOX9 are scattered over 1 Mb upstream of its TSS \[[@B21],[@B22]\]. More recently, genome-wide chromatin interaction analyses have confirmed that such long-range interactions are indeed widespread, providing evidence that the vast majority of enhancers target genes other than their nearest genes \[[@B23],[@B24]\]. Because of their genomic distribution and poorly characterized sequence features, enhancers have been difficult to identify. Only the advent of high-throughput sequencing technologies has led to large-scale screens for regulatory sequences that are now starting to reveal complete regulatory networks and signal transduction pathways in higher eukaryotes \[[@B25]\]. Such screens, however, represent a snapshot of a single cell type and set of conditions, and conclusions cannot, therefore, be easily generalized.

Previous studies have focused on identifying sequence features in either promoters or enhancers, and constructing models that describe these genomic elements, individually. Here, we show how the presence and/or absence of motifs in the promoter regions of genes with tissue-specific expression profiles can be used to reliably identify distal enhancers with analogous tissue-specific activity. Predicted enhancers are highly enriched in the loci of concordantly expressed genes (for instance, in the case of predicted liver enhancers, they are five-fold more abundant in the loci of most highly expressed liver genes than in the loci of lowly expressed liver genes), and overlap significantly with chromatin signatures predictive of enhancer activity. Experimental validation in mice supports the high accuracy of the presented method in predicting tissue-specific enhancers. With the advent of new technologies and the resulting deluge of expression data, approaches exploiting sequence features shared between promoters and enhancers hold great promise to understanding the *cis*-regulatory code encrypted in the genomes of higher organisms.

Results and discussion
======================

Promoters of tissue-specific genes contain tissue-specific signatures
---------------------------------------------------------------------

Although most promoters drive basal levels of transcription ubiquitously, some promoters are capable of controlling transcription in a tissue- and/or temporal-specific manner \[[@B26]-[@B29]\]. Genes controlled by these types of promoters are expressed in specific tissues and developmental stages, and may be induced by endogenous or exogenous factors. Here, we set out to systematically test whether promoters of genes that exhibit a particular expression profile in a given tissue contain sequence signatures that confer tissue-specificity and separate them from ubiquitous promoters. For this purpose, we collected the promoter regions (from 25 kb upstream to 0.5 kb downstream of the TSS; see Materials and methods) of the top 200 highly expressed genes in 79 different tissues and cell types \[[@B30]\] (see Materials and methods). As negative controls, we selected the promoters of the 200 least expressed genes in the same set of tissues. Although expression breadth was not considered in the construction of such gene sets, most of the genes in the sets are only expressed at high (or low) levels in the tissue of interest. Even if some genes are expressed across several tissues at high or low levels, the sets are highly non-overlapping (Supplementary notes in Additional file [1](#S1){ref-type="supplementary-material"}). Thus, while the individual genes in a given set are not strictly tissue-specific, the set itself is.

To assess the role of promoters in determining tissue-specific expression, we trained a support vector machine (SVM) for each of the 79 tissues. More precisely, to discriminate between promoters of most highly expressed and inhibited genes in each tissue, the classifiers relied on *in silico* occurrences of TF binding sites within their evolutionary conserved regions (see Materials and methods; Supplementary notes in Additional file [1](#S1){ref-type="supplementary-material"}). We evaluated the models' ability to accurately predict expression using the area under the receiver operating characteristic curve (AUC) in a five-fold cross-validation framework. Most models (73/79) can reliably distinguish promoters of genes most highly expressed in a given tissue from those of lowly expressed genes by identifying TFs associated with these tissues with median AUC values between 0.60 and 1.00 (Figure [1](#F1){ref-type="fig"}A). To be specific, for half of the models (39/79), we obtained median AUC values higher than 0.8. Moreover, when we tested a model trained on a particular tissue on the promoters of genes expressed in another tissue, we obtained relatively high AUC values mainly for related tissues (Figure S1 in Additional file [1](#S1){ref-type="supplementary-material"}), confirming that the models rely on tissue-specific motifs. We even obtained high AUC values for models in which, at first glance, we could not detect any significantly enriched motifs, such as for BM-CD71+ early erythroid cells. This result suggests the existence of different subsets of promoters, with characteristic sequence features. Modest performance is likely explained by lack of sequence features and/or relatively high heterogeneity of the promoters in the training set of the model. Thus, our models performed well even in the presence of a relatively large fraction of promoters overlapping CpG islands, but yielded higher AUC values when trained on CpG-poor promoters (with the mean fraction of promoters overlapping CpG islands being 0.58 for reliable models, as compared with 0.67 for unreliable models; Figure S2 in Additional file [1](#S1){ref-type="supplementary-material"}; Pearson's r^2^ = 0.1 with *P*-value = 0.001). Since genes expressed in the brain are strongly associated with CpG islands \[[@B31],[@B32]\], many of the models yielding low AUC values involved brain tissues. The performance of the models is also negatively correlated with the fraction of promoters enriched in TATA-box motifs (with the mean fraction of promoters containing TATA boxes being 0.49 for reliable models, as compared with 0.57 for unreliable models; Figure S3 in Additional file [1](#S1){ref-type="supplementary-material"}; r^2^ = 0.4, *P*-value = 2.8 × 10^-11^). Additionally, promoters of most highly expressed genes in reliable models are less conserved at the TSS compared to those in poor models (with average percentage of sequence identity between human and mouse of 0.63 for reliable models, as compared with 0.70 for unreliable models; Figure S4 in Additional file [1](#S1){ref-type="supplementary-material"}; r^2^ = 0.4, *P*-value = 4.4 × 10^-10^). The genes regulated by these promoters exhibit similar conservation trends. This result suggests that extensive use of promoters with tissue-specific activity could have arisen as a means to facilitate the acquisition of novel gene functions.

![**DNA motifs in human promoters predict tissue-specific expression. (A)** Area under the receiver operating characteristic (ROC) curve for 79 models trained and tested on promoters of genes highly expressed in 79 different tissues. The AUC is an overall summary of diagnostic accuracy. AUC equals 0.5 when the ROC curve corresponds to random chance and 1.0 for perfect accuracy. Reliable models (with median AUC ≥0.6) are displayed in red, while unreliable models (with median AUC ≤0.6) are displayed in gray. Models were evaluated in a five-fold cross-validation setting. **(B)** Motifs with the greatest predictive power for the liver model. The weights w of the motifs (see Materials and methods) are given in red. Motif weights have been scaled to \[-1, 1\], where 1 represents the scaled weight of the motif with highest predictive power, and -1 the scaled weight of the motif with the lowest negative predictive power (signs are preserved; see Materials and methods). The names of the features are listed near the baseline of the graph. For comparison, we include weights w for the same motif in the lung, caudate nucleus, thymus models (in different shades of gray). Similarities among the genes that were used to train the models - which reflect functional relatedness among tissues - explain similarities in the predictive power of the motif. Thus, 15% of genes that are highly expressed in liver are also highly expressed in lung, while less than 5% are in caudate nucleus and thymus.](gb-2013-14-10-r117-1){#F1}

We next observed that many of the most highly predictive motifs for tissue-specific gene expression (that is, those with the largest positive weights; see Materials and methods) for reliable models are known to be involved in the regulation of the corresponding tissue. For instance, motifs with the highest predictive power (among the top 2%) for the liver model included binding sites for HNF4A, PPARA, NR1H3, and NR2F2 (Additional file [2](#S2){ref-type="supplementary-material"}), which are among TFs that have been experimentally shown to control hepatic function and development \[[@B33]-[@B36]\]. This analysis is limited in that TFs may recognize similar binding sites and in that motif databases are partially redundant. Thus, establishing the identity of the TF that may be binding to particular motifs is not trivial. However, taken as a whole, these observations suggest that our model specifically captures key regulators of the liver transcriptional network (Figure [1](#F1){ref-type="fig"}B). Also, as expected, binding sites for the same TFs characterize models for tissues with similar gene expression profiles. For example, most brain tissues share binding sites for members of the Hox and Pax families of TFs (Additional file [3](#S3){ref-type="supplementary-material"}), confirming the correlation between motifs with high predictive power and tissue-specific regulation.

In summary, the strong predictive value of the motifs identified in promoter regions confirms that they are highly associated with tissue-specific gene expression, and substantiates the involvement of promoters in the regulation of tissue-specific expression.

Promoter signatures identify tissue-specific enhancers
------------------------------------------------------

We next assessed whether the models describing tissue-specific promoter activity could be exploited to discover enhancers. For this purpose, we applied each of the 73 reliable models trained on promoter regions to predict enhancers in the loci of genes that were among the 200 most highly or lowly expressed in the corresponding tissue (see Materials and methods). We evaluated only evolutionarily conserved non-coding sequences across the human and mouse genomes located at least 2.5 kb upstream and 0.5 kb downstream of the nearest TSS (see Materials and methods). Recent studies suggest that only about 50% are conserved in mammals, the remainder constituting lineage-specific elements (for example, \[[@B37]-[@B41]\]). This fraction, however, is expected to depend on the particular tissue where the enhancers are active. On the other hand, only 10% of the genomic sequence is conserved between mammals. This makes conservation an effective filter for enhancer identification. Indeed, integrating sequence analysis with comparative genomics has been shown to reveal important subsets of enhancers (for example, \[[@B17],[@B18],[@B42],[@B43]\]). While restricting the analysis to conserved sequences implies a reduction in sensitivity, we considered this filter essential to increase the specificity of our approach. While tissue-specific enhancers often regulate gene expression over longer distances, they tend to be enriched near genes that are expressed and functional in the tissue of interest \[[@B40],[@B44],[@B45]\]. Hence, differences in the enrichment of candidate tissue-specific enhancers between the loci of genes most highly and lowly expressed in the corresponding tissue could be used as an indicator of whether the predicted enhancers do indeed drive tissue-specific expression.

In 78% of tissues, our enhancer predictions are enriched in the loci of the 200 most highly expressed genes as compared to lowly expressed genes (*P*-values ≤0.05, Fisher's exact test; Figure [2](#F2){ref-type="fig"}A; see Materials and methods for details). The most pronounced enrichment in physiologically normal tissue was observed in heart, lung, and liver, with fold differences of at least 4.5. Moreover, for 44% of the tissues, we also found predictions in a significantly larger fraction of loci of most highly expressed genes as compared to loci of lowly expressed genes. For instance, we observed candidate liver enhancers in the 60% of the loci of most highly expressed genes, but only in 43% of the loci of lowly expressed genes (*P*-value = 0.01, computed with Fisher's exact test; Figure S5 in Additional file [1](#S1){ref-type="supplementary-material"}). Finally, for 26% of the tissues the scores of the candidate enhancers were significantly greater in the loci of most highly expressed genes as compared with those in the loci of lowly expressed genes (*P*-value ≤0.05, Wilcoxon rank-sum test; Figure S6 in Additional file [1](#S1){ref-type="supplementary-material"}), suggesting that increasing the stringency of the prediction threshold would result in even stronger associations. In total, enhancer predictions in the loci of most highly expressed genes differed significantly from their counterparts in the loci of lowly expressed genes for 85% of the tissues examined according to at least one of the above-mentioned criteria, with 14% (10) of the tissues exhibiting significant differences according to all of them (Table [1](#T1){ref-type="table"}; Additional file [3](#S3){ref-type="supplementary-material"}).

![**Genome-wide enhancer predictions. (A)** The number of enhancer predictions in the loci of highly expressed genes divided by the total number of sequences scanned in the loci of highly expressed genes (in red), as compared to the number of enhancer predictions in the loci of lowly expressed genes divided by the total number of sequences scanned in the loci of lowly expressed genes (in black), for 71 promoter-based models. Statistically significant differences are indicated by asterisks (*P*-values ≤0.05, Fisher's exact test). **(B)** Correlation between the fold enrichment between the proportions of enhancer predictions in the loci of highly expressed and lowly expressed genes with the cross-validation accuracy of the corresponding promoter-based models. **(C)** Overlap of liver enhancer predictions with strong enhancers predicted by ChromHMM in HepG2 cell lines \[[@B51]\], compared to random sequences with similar length in the loci of genes highly expressed in liver. **(D)** Overlap of liver enhancer predictions with DNase I hypersensitivity sites (DHS) in HepG2 cell lines from the ENCODE project, compared to random sequences with similar length in the loci of genes highly expressed in liver.](gb-2013-14-10-r117-2){#F2}

###### 

Tissues for which the promoter models produce the most robust sets of predictions for enhancers

  **Tissue**                   **Number of enhancer predictions**   **Fraction of loci with enhancer predictions**   **Prediction scores**      **AUC**                      
  --------------------------- ------------------------------------ ------------------------------------------------ ----------------------- --------------- ---------------- ------
  Adrenal gland                               2.70                                  1.39 × 10^-73^                           1.13            4.92 × 10^-2^   2.64 × 10^-5^    0.83
  Colorectal adenocarcinoma                   4.63                                 1.79 × 10^-155^                           1.25            2.12 × 10^-3^   4.11 × 10^-8^    0.85
  Heart                                       7.78                                 1.21 × 10^-277^                           1.31            2.82 × 10^-4^   2.19 × 10^-13^   0.93
  Kidney                                      2.76                                  1.84 × 10^-91^                           1.34            1.07 × 10^-6^   1.48 × 10^-7^    0.89
  Liver                                       4.69                                  4.99 × 10^-93^                           1.40            4.75 × 10^-4^   9.08 × 10^-5^    0.92
  Lung                                        6.53                                 1.22 × 10^-220^                           1.50            9.60 × 10^-8^   3.11 × 10^-6^    0.91
  Placenta                                    2.99                                  4.18 × 10^-83^                           1.28            4.13 × 10^-4^   5.76 × 10^-4^    0.83
  Prefrontal cortex                           1.23                                  2.27 × 10^-10^                           1.21            3.47 × 10^-6^   2.71 × 10^-2^    0.66
  Spinal cord                                 1.50                                  8.27 × 10^-38^                           1.15            2.39 × 10^-4^   1.38 × 10^-2^    0.72
  Tongue                                      1.92                                  3.17 × 10^-62^                           1.10            3.85 × 10^-2^   4.82 × 10^-5^    0.78

Only promoter-based models yielding AUC greater than 0.6 were considered in this analysis. The performance of each model in predicting enhancers was assessed by the significance of the difference between the relative number of enhancer predictions in the loci of highly expressed and lowly expressed genes with respect to the total number of scanned sequences, the significance of the difference between the fraction of loci of highly and lowly expressed genes comprising enhancer predictions, and the significance of the difference between the scores of enhancer predictions in predictions in the loci of highly and lowly expressed genes (see Materials and methods). *P*-values were computed using Fisher's exact test and Wilcoxon rank-sum test.

Fold enrichment between the proportions of enhancer predictions in the loci of the 200 most highly and lowly expressed genes is strongly correlated with the accuracy of the promoter models (Figure [2](#F2){ref-type="fig"}B). Promoter models that performed only modestly, such as those based on brain tissues (AUC ≤0.70), had limited success in predicting enhancers locus-wide (with fold enrichments reaching at most 1.3), while well-performing promoter models (AUC ≥0.90), such as those for heart, liver, kidney, and lung, achieved greater fold enrichments of at least 2.8 (for kidney). We also observed slightly higher fold enrichments between the proportions of enhancer predictions in the loci of most highly and lowly expressed genes when the difference in GC content between the former and the latter was relatively large (log2 ratio of 0.13 as compared to -0.01 for lower fold enrichments between the proportions of enhancer predictions in the loci of highly and lowly expressed genes, *P*-value = 3.2 × 10^-11^, Wilcoxon rank-sum test), suggesting a role for the GC content in the control of tissue-specific expression.

In general, enhancers predicted in the loci of the 200 most highly expressed genes in a given tissue were found to overlap extensively with experimental and computational enhancer marks characteristic of functional regulatory regions. For instance, candidate tissue-specific enhancers were found to be significantly enriched (*P*-value ≤0.05, Fisher's exact test) in binding sites for TFs within regulatory networks that are known to be important in the respective tissues, such as MYC and NFKB1 in heart, and HNF4A and SP1 in liver \[[@B46]-[@B49]\] (data not shown). The combined collection of enhancers predicted in the loci of the 200 most highly expressed genes in each of the tissues considered significantly overlap with ORegAnno, a manually curated collection of regulatory sequences \[[@B50]\], featuring a two-fold enrichment (*P*-value \<0.001, computed based on 1,000 randomized sequences genome-wide). Also, our enhancer predictions are enriched for specific epigenetic histone marks generally associated with distal transcriptional regulation, as suggested by 41% of predicted enhancers overlapping ChromHMM predictions for strong and weak enhancers (1.5-fold enrichment, *P*-value \<0.001, computed based on 1,000 randomized sequences genome-wide \[[@B51]\]). In addition, our predictions are significantly associated with the enhancer chromatin signature H3K4me1 (1.3-fold enrichment, *P*-value ≤0.001, computed based on 1,000 randomized sequences genome-wide) and DNase I hypersensitive sites (DHSs) in different human cell lines, with a total of 42% of predicted enhancers overlapping 1% of the DHSs (1.6-fold enrichment, *P*-value \<0.001, computed based on 1,000 randomized sequences genome-wide). In particular, liver enhancer predictions extensively overlap with different enhancer marks, such as p300 binding, chromatin marks, and DHSs (Figure S7 in Additional file [1](#S1){ref-type="supplementary-material"}). For example, 29% of liver enhancer predictions overlap chromatin marks and ChromHMM enhancer predictions for the HepG2 hepatocellular carcinoma cell line, providing additional evidence for the tissue-specificity of the activity of the predicted enhancers (Figures [2](#F2){ref-type="fig"}C,D; Figure S8 in Additional file [1](#S1){ref-type="supplementary-material"}). Substantial overlap is also observed for other classifiers with DHSs (Figure S9 in Additional file [1](#S1){ref-type="supplementary-material"}). Finally, we found that enhancer predictions are significantly enriched in matching p300 embryonic brain, limb, and heart enhancers (2.5-fold enrichment, *P*-value \<0.001, computed based on 1,000 randomized sequences genome-wide, \[[@B45],[@B52]\]).

Taken together, these observations are consistent with our promoter-based models being able to predict enhancers that drive specific expression of neighboring genes in different tissues.

Experimental assays validate tissue-specific activity of promoter-based enhancer predictions
--------------------------------------------------------------------------------------------

The most reliable evidence for the accuracy of our promoter-based models in predicting tissue-specific enhancers is the experimental verification of their regulatory activity *in vivo*. Substantiated by the consistent results from the computational analysis, we chose to validate a subset of liver enhancer predictions in the loci of highly expressed liver genes using a mouse liver reporter assay \[[@B53],[@B54]\]. We selected, as described in detail below, 12 out of the total of approximately 400 regions with predicted liver enhancer activity (Table [2](#T2){ref-type="table"}) and 5 regions with no predicted activity as controls (Table [3](#T3){ref-type="table"}) for functional testing. Importantly, we tried to ensure that the enhancer predictions tested were not significantly different from the whole set of predictions, and chose controls exclusively based on their score. Thus, differences between enhancer predictions and controls observed for other sequence properties simply reflect an association between high scores and the existence of functional constraints, rather than bias in the selection of the sequences. Liver enhancer predictions selected for validation had an average score of 1.79, and were distributed across the complete range of scores (Figure S10A in Additional file [1](#S1){ref-type="supplementary-material"}). Additionally, liver enhancer predictions selected for validation are located at an average distance to the nearest TSS of 7.3 kb, and are not significantly different from the entire set of liver enhancer predictions (Figure S10B in Additional file [1](#S1){ref-type="supplementary-material"}). Also, liver predictions selected for validation did not exhibit statistically significant differences in the level of evolutionary constraint compared to the entire set of liver predictions, with an average phastCons score \[[@B55],[@B56]\] of 0.38 (Figure S10C in Additional file [1](#S1){ref-type="supplementary-material"}). Finally, while half of the regions with predicted liver enhancer activity were selected randomly, the remaining half was selected randomly among those predictions overlapping with strong enhancer predictions by ChromHMM in HepG2 cell lines \[[@B51]\]. Controls were selected randomly among sequences that had scores in the bottom half of the score distribution for the full set of scanned sequences, had an average score of -1.70, were located 27.5 kb away from the nearest TSS, and had an average phastCons score of 0.37. Each liver enhancer prediction and control was cloned upstream of a minimal promoter element and the luciferase reporter gene (pGL4.23; Promega). Each construct was then injected using the hydrodynamic tail vein injection assay into at least three different mice, and liver enhancer activity was assayed after 24 h by measuring luciferase levels (see Materials and methods).

###### 

***In vivo*assay of 12 liver enhancer predictions in mouse**

  **ID**   **Coordinates \[hg18\]**        **Score**  **Location**                                  **Activity**   **Chromatin state**^**a**^
  -------- ------------------------------ ----------- -------------------------------------------- -------------- ----------------------------
  E1       **Chr16:30009197-30009301**     **3.07**   **Intronic (*TBX6*)**                           **Yes**                **No**
  E7       Chr10:82023332-82023434           2.60     Intergenic (3\' UTR of *MAT1A*)                    No                   Yes
  E2       Chr17:69962796-69962894           2.21     Intergenic (4.5 kb downstream of *GPRC5C*)         No                    No
  E8       **Chr1:31679030-31679149**      **1.94**   **Intronic (*SERINC2*)**                        **Yes**               **Yes**
  E12      **Chr3:134934911-134935091**    **1.81**   **Intronic (TF)**                               **Yes**               **Yes**
  E4       **Chr11:72138832-72139119**     **1.83**   **Intronic (ARAP1)**                            **Yes**                **No**
  E5       **Chr17:69957921-69958023**     **1.30**   **Intergenic (3′ UTR of*GPRC5C*)**              **Yes**                **No**
  E10      **Chr17:69951076-69951329**     **1.57**   **Intronic (*GPRC5C*)**                         **Yes**               **Yes**
  E3       Chr11:72162942-72163179           1.47     Intronic (*STARD10*)                               No                    No
  E9       Chr11:72168912-72169046           1.33     Intronic (*STARD10*)                               No                   Yes
  E11      **Chr11:72166225-72166509**     **1.36**   **Intronic (*STARD10*)**                        **Yes**               **Yes**
  E6       Chr17:17439720-17439913           1.04     Intergenic (4 kb upstream of *PEMT*)               No                    No

^a^Overlaps with \'strong enhancer\' Chromatin State Segmentation by HMM from Broad Institute, MIT, and MGH in HepG2 cell lines. Enhancer predictions for which we observed *in vivo* activity in mouse liver are highlighted in bold.

###### 

***In vivo*assay of regions with no predicted regulatory activity (controls)**

  **ID**   **Coordinates \[hg18\]**    **Score**  **Location**                                         **Activity**
  -------- -------------------------- ----------- --------------------------------------------------- --------------
  C1       Chr15:56263227-56263340       -2.22    Intronic (*AQP9*)                                         No
  C2       Chr6:26030369-26030485        -2.03    Intronic (*SLC17A2*)                                      No
  C3       Chr22:19494975-19495083       -1.26    Intronic (*PI4KA*)                                        No
  C4       Chr5:138482622-138482789      -1.67    Intronic (*SIL1*)                                         No
  C5       Chr9:96485498-96485627        -1.32    Intergenic (50 kbp upstream of *FBP1* and C9orf3)         No

We observed statistically significant enhancer activity for 7/12 (58%) enhancer predictions compared to empty-vector-injected mice, with no significant difference depending on how predictions were selected (two-tailed Fisher's exact test). The significant increase in luciferase activity driven by liver enhancer predictions ranged from 2.0- to 6.4-fold relative to the empty vector. By comparison, 0/5 of the controls activated the luciferase reporter (false discovery rate adjusted q \< 0.05; Figure [3](#F3){ref-type="fig"}, Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}; Additional file [4](#S4){ref-type="supplementary-material"}). These data confirm that a large fraction of our liver enhancer predictions function as enhancers *in vivo*, regulating expression in the liver.

![**Experimental validation of liver enhancer predictions using the hydrodynamic tail vein enhancer assay.** On each injection day, we also injected an empty pGL4.23\[luc2\] vector and a known liver enhancer of the *ApoE* gene as negative and positive controls, respectively. At least three mice were injected per construct. Statistical significance was tested using Student's *t*-test followed by multiple testing adjustment with Benjamini-Hochberg's method. The asterisks indicate statistical significance to control at adjusted *P*-value ≤0.05.](gb-2013-14-10-r117-3){#F3}

Promoter-based models have the potential of shedding light on the human regulatory landscape
--------------------------------------------------------------------------------------------

We applied each of the 73 reliable models trained on promoter regions to the entire sequence of the human genome. We scanned approximately 1,200,000 non-promoter CNEs across the human and mouse genomes for enhancer signatures (see Materials and methods). No model generated more than 160,000 enhancer predictions, with an average of approximately 51,000. We observed substantial overlap among enhancer predictions for related tissues (Figure S11 in Additional file [1](#S1){ref-type="supplementary-material"}), in part reflecting the resemblance between promoter-based models of tissues with similar gene expression profiles, but also indicating the existence of shared regulatory pathways. Thus, from all sequences scanned, approximately 900,000 (73%) were considered enhancer predictions for at least one of the models, with an average of approximately 12,000 non-redundant enhancer predictions per tissue, consistent with current ChIP-seq findings \[[@B29]\]. Although we estimate the false positive rate at approximately 5% based on the number of enhancer predictions in the loci of lowly expressed genes, a caveat of our approach is that local differences in the composition of the human genome could result in overall higher false positive rates. Also, consistent with the literature (for example, \[[@B57]\]), we found that most loci in the genome contain more than one enhancer. Indeed, without considering redundancy among predictions, we predict an average of four enhancers per locus per model, with the exact number depending on the tissue (Figure S12 in Additional file [1](#S1){ref-type="supplementary-material"}).

We then analyzed the distribution of enhancer predictions across the genome relative to genes. From all sequences that were classified as enhancer predictions by at least one of the models, 55% mapped within intronic regions, 43% mapped within intergenic regions, and the remaining 2% to UTRs. The trend is consistent for all tissues, in that the proportion of intronic enhancer predictions is always greater than that of intergenic predictions. Overall, tissue-specific enhancer predictions tend to be located closer to TSSs, and in particular, near TSSs of highly expressed genes in matching tissues. For example, there was more than 3-fold enrichment in liver enhancer predictions within 100 kb of the TSS of the 200 most highly expressed genes in the liver (*P*-value \<0.001, computed based on 1,000 randomized sequences genome-wide), a number that increased to 4-fold enrichment within 10 kb of the TSS (*P*-value \<0.001, computed based on 1,000 randomized sequences genome-wide). Furthermore, stronger enhancer predictions are closer to TSSs than weaker predictions, with, for instance, the strongest 1% of liver enhancer predictions being located 40 kb away from the nearest TSS as compared to 73 kb for the complete set of liver enhancer predictions. These results are in agreement with the literature, and suggest that the functional relevance of a genomic region depends on its position relative to the TSS \[[@B58]\]. Our enhancer predictions are enriched near genes annotated with relevant gene ontology terms. For example, we found more than five-fold enrichment in liver enhancer predictions within the loci of genes associated with 'positive regulation of hepatic stellate cell activation', 'liver development', and 'positive regulation of hepatocyte differentiation' (*P*-values \<0.05, Fisher's exact test), as well as enrichment for genes with critical liver functions, such as 'positive regulation of cholesterol metabolic process' (*P*-value = 2.7 × 10^-14^, Fisher's exact test), 'triglyceride lipase activity' (*P*-value = 6.0 × 10^-8^, Fisher's exact test), and sucrose, maltose, and trehalose metabolic processes (all *P*-values \<0.05, Fisher's exact test).

Although all our tissue-specific enhancer predictions were selected from conserved non-coding sequences across the human and mouse genomes, they exhibit different levels of conservation according to their phastCons scores (Figure S13 in Additional file [1](#S1){ref-type="supplementary-material"}). For example, liver and heart enhancer predictions in the loci of highly expressed genes are significantly more conserved than the sequences used as basis for making predictions (0.41 versus 0.34, and 0.43 versus 0.37, with *P*-values 1.1 × 10^-32^ and 5.6 × 10^-33^, respectively, calculated using the Wilcoxon rank-sum test). For models that did not perform well in terms of their fold enrichment between the proportion of enhancer predictions in the loci of highly and lowly expressed genes (for example, skin and fetal brain), we observed significantly less constrained predictions. We observed similar trends when we applied our promoter-based classifiers to investigate unconstrained sequences (see Supplementary notes in Additional file [1](#S1){ref-type="supplementary-material"}).

In summary, our results indicate the existence of largely disjoint sets of tissue-specific regulatory sequences located in the neighborhood of their potential target genes. They also confirm an important role for evolutionarily constrained sequences, in that 73% of sequences conserved across mammals exhibit regulatory potential. Finally, consistent with previous studies, they support a role for both promoters and enhancers in determining spatiotemporal patterns of gene expression.

Conclusions
===========

By analyzing the sequence of promoters of tissue-specific genes, we confirmed that tissue-specific promoters and enhancers share TF binding motifs within the loci of their cognate genes. Moreover, we observed that regulatory information in the promoters of tissue-specific genes is predictive of the enhancers targeting these genes. For 73/79 tissues, we could reliably distinguish between highly and lowly expressed genes based exclusively on the presence or absence of putative motifs (AUC ≥60%). Although similar cut-offs have been recently employed (for example, \[[@B18],[@B59]\]), we recognize that the half of the models exhibiting modest performances (AUC ≤80%) might have limited predictive value. It is, however, important to note that the reported AUCs represent the lower bound of the classifier accuracy due to the fact that the strength of the tissue-specificity enhancer signal is expected to vary among the promoters of tissue-specific genes. Promoters containing only weak signals will inherently deflate the classification AUC estimates. To further address the performance of the classifiers at predicting tissue-specific enhancers, we introduced a panel of independent computational and experimental tests, which ultimately validated our analysis. Many of the TFs binding to the motifs that are identified as relevant to each of these models are known to play a fundamental role in the development or maintenance of normal function of the corresponding tissues. We showed that the motifs found in promoter regions can be used to predict enhancers with matching tissue-specificity. The accuracy of our tissue-specific enhancer predictions by promoter-based models is supported by a highly significant association of enhancer predictions with the genes most highly expressed in a given tissue, and by a significant overlap of predictions with experimentally identified tissue-specific enhancers.

More importantly, 58% (7/12) of liver enhancer predictions generated by the promoter-based model drove luciferase expression in the liver following hydrodynamic tail vein injection in mice, whereas none of the five negative controls did.

Six of the seven validated liver enhancers were located within introns (for the genes *TBX6*, *SERINC2*, *TF*, *ARAP1*, *STARD10*, and *GPRC5C*), while the remaining prediction was in the immediate vicinity of *GPRC5C*. These genes have been previously reported as moderately to highly expressed in liver and gallbladder \[[@B60]\]. For example, although the specific function of *GPRC5C* is unknown, the gene is highly expressed in the liver and has been suggested to play a role in signaling events when induced by retinoic acid \[[@B61]\]. In addition to other motifs, liver enhancer predictions that exhibited luciferase activity contained predicted binding sites for 5 to 11 out of 27 known liver TFs (Additional file [5](#S5){ref-type="supplementary-material"}). Although each of the critical liver TFs PPARA, PPARG, NR2F2, and HNF4A had binding sites in 6/7 (86%) sequences, no single TF had a binding site in all 7 sequences that exhibited luciferase activity, highlighting the ability of our method to model flexible regulatory sequence encryptions. In turn, each of the 7 sequences included binding sites for at least 2 of these 4 TFs, and 4/7 (57%) for all 4. The 5 liver enhancer predictions that exhibited no significant luciferase activity contained binding sites for 4 to 8 out of 27 known liver TFs. HNF4A had binding sites in all 5 sequences, PPARA and NR2F2 had binding sites in 4/5 (80%) sequences, and PPARG in 3/5 (60%). With one exception, each of the sequences included binding sites for at least 2 of these 4 TFs, and 3/5 (60%) for all 4. For comparison, 87% of all sequences scored by the liver promoter-based model contained 1 to 18 out of 27 known liver TFs. HNF4A had binding sites in 28% of the sequences. Only 11% of the sequences had binding sites for at least two TFs among PPARA, PPARG, NR2F2, and HNF4A, and 7% for all four TFs. Despite limitations in the accuracy of the TF binding site predictions and despite the fact that many motifs may be nonfunctional \[[@B62]\], our results suggest that particular combinations of TFs, rather than single TFs, are necessary to establish liver transcription. In addition, the function of assayed sequences may be subject to activation or inhibition by additional *cis*- and *trans*-regulatory elements. For example, enhancer activity might be induced by hormones or drugs under particular conditions \[[@B63]\] or depend on neighboring functional elements that are absent in the construct used for the experiment. This and other phenomena could produce false-negative observations in the reporter assays. In any case, the experimental data presented here provide independent and robust validation of the enhancer predictions obtained with the promoter-based models, and lend further support for the hypothesis that the specificity of interactions between enhancers and promoters is at least partly due to the binding of tissue-specific TFs.

Our models predict multiple tissue-specific enhancers per locus and per tissue, as well as multiple tissues or domains of activity for most enhancers. This redundancy, which has long been reported (for example, \[[@B64]-[@B66]\]), may serve to increase the robustness of the regulatory network \[[@B67]\]. Furthermore, it is likely that apparently redundant enhancers activate gene expression in different cell types and/or under different developmental stages or conditions \[[@B68]-[@B71]\]. The genomic distribution of enhancers is also likely to vary depending on the function of their target genes. For example, the loci of transcription factors and developmental genes are known to contain particularly high densities of CNEs, many of which act as distal enhancers \[[@B72]-[@B77]\]. More recently, advances in technical approaches, such as chromosome conformation capture and its derivatives, have confirmed these findings independent of sequence conservation \[[@B24],[@B78]\]. We observed that relatively long loci, such as those of genes expressed in brain tissues, featured more enhancer predictions per locus compared to short loci. However, some compact loci, such as those of genes highly expressed in liver, lung, and heart, contained a relatively large number of enhancer predictions, providing evidence for a particular need for fine-tuning the expression level in these tissues. Furthermore, the level of conservation of enhancer sequences is likely to depend, as other studies suggests (for example, \[[@B79],[@B80]\]), on their particularly activity, although we found that, for all models, a large proportion of the enhancer predictions is likely to be conserved across mammals.

Finally, our results add further evidence for a significant role of both promoters and enhancers in determining tissue specificity. This role is supported by several examples from the literature \[[@B14],[@B81],[@B82]\]. Different enhancer-promoter preferences would provide an additional level of transcriptional control, assisting in establishing the favorable interactions, for instance, between enhancers and their cognate promoters when they are distant, or between enhancers and their cognate promoters within a gene cluster. The intimate coordination of promoters and enhancers in regulating tissue-specific transcription has immediate practical consequences. It makes it possible to describe the complex regulatory landscape of higher eukaryotes, and eventually identify regulatory elements located hundreds of kilobases away from their target gene, based solely on the analysis of proximal regulatory elements. DNA microarrays and, more recently, RNA-seq are currently being used to profile the transcriptomes of a diverse range of cell/tissue types, conditions, and species. As more expression data become available, particularly in the context of large projects such as ENCODE \[[@B83]\] and the 1000 Genome Project \[[@B84]\], it is our belief that the application of approaches such as the one we are proposing here will result in important new insights and improve our understanding of transcriptional regulation. Such projects are also generating a wealth of epigenetics information that can be easily integrated with our models to reveal genomic signatures controlling transcription.

Materials and methods
=====================

Gene annotation and expression data
-----------------------------------

GNF Novartis Gene Expression Atlas version 2 \[[@B30]\] was extracted from the gnfAtlas2 table and mapped to the RefSeq \[[@B85]\] genes using the knownToGnfAtlas2 and kgXref tables (all tables are available in the UCSC Genome Browser database \[[@B86]\]). Thereby, we obtained expression profiles in 79 tissues (721 B lymphoblasts, BM-CD105+ endothelial, BM-CD33+ myeloid, BM-CD34+, BM-CD71+ early erythroid, PB-BDCA4+ dentritic cells, PB-CD14+ monocytes, PB-CD19+ B cells, PB-CD4+ T cells, PB-CD56+ natural killer (NK) cells, PB-CD8+ T cells, adipocyte, adrenal cortex, adrenal gland, amygdala, appendix, atrioventricular node, bone marrow, bronchial epithelial cells, cardiac myocytes, caudate nucleus, cerebellum, cerebellum peduncles, ciliary ganglion, cingulate cortex, colorectal adenocarcinoma, dorsal root ganglion, fetal brain, fetal liver, fetal lung, fetal thyroid, globus pallidus, heart, hypothalamus, kidney, leukemia chronic myelogenous (k562), leukemia lymphoblastic (molt4), leukemia promyelocytic (hl60), liver, lung, lymph node, lymphoma Burkitts Daudi, lymphoma Burkitts Raji, medulla oblongata, occipital lobe, olfactory bulb, ovary, pancreas, pancreatic islets, parietal lobe, pituitary gland, placenta, pons, prefrontal cortex, prostate, salivary gland, skeletal muscle, skin, smooth muscle, spinal cord, subthalamic nucleus, superior cervical ganglion, temporal lobe, testis Leydig cell, testis, testis germ cell, testis interstitial, testis seminiferous tubule, thalamus, thymus, thyroid, tongue, tonsil, trachea, trigeminal ganglion, uterus, uterus corpus, whole blood, whole brain) for 13,977 human genes. Overall, 5,023 genes were considered \'most highly expressed\' in at least one of the 79 tissues. Additionally, 6,531 genes were least expressed in these tissues.

Locus definition
----------------

In order to define gene loci, we first clustered together all overlapping transcripts in the refGene.txt and knownGene.txt tables (available in the UCSC Genome Browser database \[[@B86]\]), and then assigned the closest half of the intergenic sequence separating two genes to each of the corresponding gene loci. Although the genes that are closest to the enhancers are reasonable target genes, there are many known cases of enhancers located in introns of genes that are not their targets, as well as enhancers several kilobases away from their targets, with unrelated genes in between. Current integrative approaches result only in modest improvement in enhancer-target gene associations (for example, \[[@B87]\]), often requiring non-available data. Recently, a method based on Hi-C has been introduced to identify genome-wide functional domains based on higher-order chromatin interactions \[[@B5]\]. However, comparisons between alternative methods are limited because of the lack of an appropriate reference or gold standard.

Promoter annotation and definition for promoter modeling
--------------------------------------------------------

Promoter regions were defined as encompassing a 3 kb region (2.5 kb upstream and 0.5 kb downstream of the TSS), relative to 5′ TSSs of all transcripts annotated in RefSeq \[[@B85]\]. Although the total length is arbitrary, it intends to span both the core and proximal promoter regions. In most cases, the signal that turned out to be relevant for the models was detected within 500 bp of the TSS (Figure S14 in Additional file [1](#S1){ref-type="supplementary-material"}).

Gene expression values for each of the promoters of the most highly and least expressed genes in each of the 79 tissues considered were extracted from \[[@B88]\]. Probe IDs were converted to UCSC Known Gene IDs using \[[@B89]\]. Subsequently, UCSC Known Gene IDs were converted to gene symbols and RefSeq IDs using \[[@B90]\]. Expression values for transcripts with the same gene symbol were averaged together. The 200 most highly and least expressed genes with different gene symbols were selected. TSSs of all RefSeq IDs associated with those gene symbols were then used to define 3 kb promoter regions.

Sequence conservation of promoter regions
-----------------------------------------

Sequence identity of promoter regions was determined based on genome-genome alignment of human and mouse (from the net/chain track at UCSC \[[@B86]\]), using the hg18 and mm9 genome assembly, respectively.

Sequence conservation of coding regions
---------------------------------------

As an indicator of coding conservation across species we used the proportion of orthologs of human genes found in other eukaryotic species (HomoloGene Build 64 \[[@B91]\]).

Motif occurrences
-----------------

Presence or absence of putative motifs was determined scanning the sequence for 775 motifs in TRANSFAC \[[@B92]\] and JASPAR \[[@B93]-[@B95]\] using MAST \[[@B96]\] with default parameters.

### Motif over-representation in promoter regions

Over-representation of 775 motifs representing TF binding sites in TRANSFAC and JASPAR among promoter regions of the 200 most highly expressed genes in each of the 79 tissues considered was determined by comparing the promoter regions of the 200 most highly expressed genes to the promoters of the 200 least expressed genes in the corresponding tissue. The entire length of the promoter region (-2.5 kb to +0.5 kb with respect to the TSS) was searched for motif occurrences with MAST. The numbers of putative TF binding site occurrences in each set of promoters were compared using the Wilcoxon rank-sum test.

Transcription factors associated with transcription factor binding sites
------------------------------------------------------------------------

TF annotation for position-weight matrices (PWMs) was obtained from TRANSFAC \[[@B92]\], JASPAR \[[@B93]-[@B95]\], and the Broad Institute (MSigDB \[[@B97]\]).

CpG islands and TATA-box motifs
-------------------------------

Annotation for CpG islands was obtained from the \'cpgIslandExt\' UCSC track of the hg18 assembly of the human genome database \[[@B86]\]. Presence or absence of TATA-box motifs in promoter regions was determined by scanning the sequence for TATA-box motifs in TRANSFAC \[[@B92]\] using MAST \[[@B96]\] with default parameters.

Separating promoters of most highly and lowly expressed genes
-------------------------------------------------------------

### Training data

The promoter regions (-2.5 kb to +0.5 kb with respect to the TSS, based on RefSeq annotation \[[@B85]\]) of the 200 most highly expressed genes (positive set) were compared to the promoters of 200 genes with the lowest expression (negative set) in each of the 79 considered tissues.

### Sequence representation

Next, we converted the DNA sequence of each promoter into a set of TF binding site feature vectors. We first identified all CNEs (at least 70% sequence identity between human and mouse \[[@B98]\]) within each promoter sequence. Next, we ran the program MAST \[[@B96]\] with default parameters to identify motif occurrences in the CNEs matching 775 known TF binding sites from the TRANSFAC \[[@B92]\] and JASPAR \[[@B93]-[@B95]\] databases. With this information, each CNE was then transformed into a 775-dimensional TF binding site feature vector, where each feature corresponds to the number of the corresponding TF binding site occurrences in the sequence of the CNE. There were 2.4 feature vectors (one per CNE) in a promoter, on average.

For a given classifier, the training set contained as many feature vectors as the number of CNEs found in the promoters of the 200 most highly expressed genes (positive set) plus the number of CNEs found in the promoters of the 200 genes with the lowest expression (negative set). Because promoter regions may overlap, the sets included only unique CNEs.

### Classifiers

Linear SVMs \[[@B99]\] were used to find features relevant to distinguish between the CNEs in promoters associated with highly expressed genes (positive class) and those in promoters associated with lowly expressed genes (negative class). For each tissue, we trained a SVM on an average of 553 feature vectors representing CNEs in the promoter regions of highly expressed genes and 525 feature vectors representing CNEs in the promoter regions of lowly expressed genes. We optimized the weight of the positive class *w*~1~ by performing a grid search. The optimal value was chosen from $w_{1} = \frac{n^{+}}{n^{-}}\gamma$, where $\gamma \in \left\{ {\frac{1}{3},\frac{2}{3},1,\frac{4}{3},\frac{5}{3}} \right\}$, *n*^+^ is the number of signal sequences, and *n*^-^ is the number of control sequences.

A double-loop cross-validation was used to assess the accuracy of the classifier. In each fold of the cross-validation, we used four-fifths of the members of the positive and negative classes to identify a \'consistent\' set within the positive class. This strategy is aimed at identifying sequences that are consistent with each other, in an effort to reduce the natural heterogeneity of the promoter sets. More precisely, in each fold of the cross-validation, for each promoter *P* in the positive class in the four-fifths of the data that was used to identify a consistent set, we trained a model excluding all sequences associated with *P*. Subsequently, we used that model to score each of the sequences associated with *P*. Finally, among those sequences, we randomly selected two positive-scoring ones to represent *P* in a \'consistent\' positive set. After repeating this for all promoters in the positive class, we obtained a \'consistent\' positive set. This consistent positive set was used together with the remaining one-fifth of the members of the negative class to train a final classifier. The accuracy of this final classifier was evaluated using a standard five-fold cross-validation. The entire procedure was repeated for each of the five cross-validation folds, and the cross-validation was repeated five times. AUC was used as criterion for optimality. This double-loop cross-validation has been successfully applied to the enhancer prediction problem in the past (for example, \[[@B17]\]).

Figure S15 in Additional file [1](#S1){ref-type="supplementary-material"} illustrates the variation of the size of the consistent positive set for the 79 tissues considered. In our cross-validation framework, the consistent positive set contained an average of 157 CNEs, representing 35% of the training data. However, the size of the consistent positive set depends on the particular tissue, ranging from 39 (10%) to 269 (41%) CNEs for PB-CD56+ NK cells and medulla oblongata, respectively. For PB-CD56+ NK cells the consistent positive set also contained the smallest fraction of CNEs, while the largest fraction was obtained for uterus corpus (51%).

#### Linear SVMs

Training a linear SVM classifier is equivalent to solving the following constrained optimization problem \[[@B100]\]:

Given the training samples $T = \left\{ \left( {x_{i},y_{i}} \right) \middle| x_{i} \in {\mathbb{R}}^{p},y_{i} \in \left\{ {- 1,1} \right\} \right\}_{i = 1}^{n}$, find the values of w, b and ξ~i~ that minimize

$$\frac{1}{2}w^{T}w + C\sum\limits_{i = 1}^{n}\xi_{i}$$

satisfying the constraints

$$y_{i}\left( {w^{T}x_{i} + b} \right) \geq 1 - \xi_{i}\forall i = 1,\ldots,n$$

and

$$\xi_{i} \geq 0\forall i = 1,\ldots,n$$

The decision function of the classifier for an unknown sample x is given by:

$$f\left( x \right) = {sign}\left( {w^{T}x + b} \right)$$

The dual form of this problem can be described as follows: Given the training samples $T = \left\{ \left( {x_{i},y_{i}} \right) \middle| x_{i} \in {\mathbb{R}}^{p},y_{i} \in \left\{ {- 1,1} \right\} \right\}_{i = 1}^{n}$, find the values $\left\{ \alpha_{i} \right\}_{i = 1}^{n}$ that maximize

$$\sum\limits_{i}\alpha_{i} - \frac{1}{2}\sum\limits_{i = 1}^{n}\sum\limits_{j = 1}^{n}\alpha_{i}\alpha_{j}y_{i}y_{j}x_{i}^{T}x_{j}$$

satisfying the constraints

$$0 \leq \alpha_{i} \leq C\forall i = 1,\ldots,n$$

and

$$\sum\limits_{i = 1}^{n}a_{i}y_{i} = 0.$$

Samples x~i~ for which a~i~ ≥ 0 are called support vectors.

The vector w can be computed in terms of α~i~ as:

$$w = \sum\limits_{i = 1}^{n}a_{i}y_{i}x_{i}$$

and, therefore, contains the weighted features of the support vectors.

#### SVM parameter selection

Linear SVMs have only one parameter, *C*, which controls the trade-off between errors on the training data and margin maximization. We found that the performance of the Hb enhancer classifier was relatively stable with respect to changes in *C*. We estimated *C* based on the training data as $\left\lbrack {\frac{1}{n}\sum\limits_{i = 1}^{n}\left| x_{i} \right|} \right\rbrack^{- 2}$. Misclassifications are penalized differently depending on the class of sequences, proportionally to the total number of sequences in each class.

Predictive power of the motifs
------------------------------

After obtaining a linear SVM model, the weight vector w can be used to decide the relevance of each feature \[[@B101]\]. The larger \|w~j~\|, the more important role of feature *j* in the decision function. On these grounds, we used the weights *w*~*j*~ to assess the predictive power of each motif.

### Scaled SVM weights

To make motif weights comparable across different SVM classifiers, we scaled them preserving their sign according to:

$$\mathit{scaled}\ w_{j} = \left\{ \begin{matrix}
{- \left( {1 - \frac{w_{j} - w_{\mathit{\min}}}{- w_{\mathit{\min}}}} \right),} & {\mathit{if}\ w_{j} < 0} \\
{\frac{w_{j}}{w_{\mathit{\max}}},} & {\mathit{if}\ w_{j} \geq 0} \\
\end{matrix} \right),$$

where

$$w_{\min} = \left\{ \begin{matrix}
{\min\limits_{j}\left\{ w_{j} \right\},} & {\mathit{if}\ \min\limits_{j}\left\{ w_{j} \right\} < 0} \\
{0,} & \mathit{otherwise} \\
\end{matrix} \right)$$

and

$$w_{\max} = \left\{ \begin{matrix}
{\max\limits_{\mathit{j}}\left\{ w_{j} \right\},} & {\mathit{if}\ \max\limits_{j}\left\{ w_{j} \right\} > 0} \\
{0,} & \mathit{otherwise} \\
\end{matrix} \right)$$

GC content of transcription factor binding sites
------------------------------------------------

Sequence motifs representing motifs are usually encoded as PWMs. A PWM is a matrix containing the relative frequency of each of the four possible nucleotides at each position of a motif, which are estimates of the corresponding probabilities.

To obtain the GC content of a motif, we calculated and averaged the probability of observing G or C at each position of the corresponding PWM.

In order to assess the contribution of the GC content to the performance of the promoter-based enhancer models, we trained 5 models using the aforementioned strategy, each time replacing the original 775 PWMs by an equally large collection of PWMs, in which the nucleotide probabilities of each PWM have been randomly permuted.

Difference in GC content between two loci
-----------------------------------------

Differences in GC content between loci of highly and lowly expressed genes were expressed as the natural logarithm of the ratio between the GC content of the loci of highly expressed genes and the GC content of the loci of lowly expressed genes.

Enhancer predictions
--------------------

We applied our promoter-based models as genome-wide predictors of human enhancers to both conserved and non-conserved sequences. In particular, for a given tissue, when we refer to predictions in the loci of the (200) most highly and lowly expressed genes, we imply predictions in the loci of the 200 genes with highest and lowest expression levels whose promoters were used to train the corresponding classifier.

### Prediction of conserved enhancers

First, we selected CNEs with at least 70% identity across the human and mouse genomes \[[@B98]\] located at least 2.5 kb upstream and 0.5 kb downstream of TSSs annotated in refGene.txt and knownGene.txt tables (available in the UCSC Genome Browser database \[[@B86]\]). Thus, we scored approximately 1,200,000 CNEs across the human genome, with an average length of 249 bp. In particular, the loci of the 200 most highly expressed genes in any of the 73 tissues considered comprised, on average, 85 CNEs, and comprised a total of 500,000 CNEs, while the loci of the 200 genes with lowest expression in any of the 73 tissues considered included an average of 108 and a total of 750,000, respectively.

### Prediction of non-conserved enhancers

Second, we scanned the genome using a sliding window approach. Windows overlapping the sequence 2.5 kb upstream and 0.5 kb downstream of the nearest TSS according to the refGene.txt and knownGene.txt tables (available in the UCSC Genome Browser database \[[@B86]\]) were excluded from further analysis. For the size of the window, we chose the average length of the conserved region between human and mouse \[[@B98]\], namely 230 bps. The sliding window is shifted by 115 bps. A given sequence was considered an enhancer prediction (or enhancer candidate) if its score was greater than *s* = *min*(0, *δ*), where *δ* is the lowest score of the top 5% sequences scored in the control loci.

Computational evaluation of genome-wide enhancer predictions
------------------------------------------------------------

### Functional analysis

To assess whether these elements disproportionally occur near genes with particular functions, we obtained the Gene Ontology \[[@B102]\] (CVS version 1.2811, GOC Validation Date March 28, 2012) annotations of the closest neighboring UCSC known genes \[[@B103]\] for all non-coding elements, and assigned those annotations to each element. Gene-to-GO mapping was achieved by combining the UCSC refGene.txt and knownGene.txt tables and GOA \[[@B104]\] association table using UniProt IDs. *P*-values were corrected for multiple testing using Bonferroni's method \[[@B105]\].

### Fold enrichment of enhancer predictions in the loci of the 200 most highly expressed genes as compared to the loci of lowly expressed genes

In order to account for differences in the length of the loci, we did not directly compare the number of enhancer predictions in the loci of the 200 most highly expressed genes in a given tissue with the number of enhancer predictions in the loci of lowly expressed genes in that same tissue, but the numbers of enhancer predictions divided by the numbers of scanned sequences for loci of highly and lowly expressed genes. Therefore, the fold enrichments in Table [1](#T1){ref-type="table"} and Additional file [3](#S3){ref-type="supplementary-material"} were computed as the ratio of two proportions: (i) the total number of enhancers predicted in the loci of the 200 most highly expressed genes divided by the total number of sequences scanned in the loci of highly expressed genes; and (ii) the total number of enhancers predicted in the loci of lowly expressed genes divided by the total number of sequences scanned in the loci of lowly expressed genes. For the 73 tissues evaluated and focusing only on CNEs across the human and mouse genomes, these proportions averaged 0.04 for loci of highly expressed genes, and 0.03 for loci of lowly expressed genes. In the case of whole-loci predictions, these proportions averaged 0.03 for loci of the 200 most highly expressed genes, and 0.02 for loci of lowly expressed genes.

### Fraction of loci comprising enhancer predictions

The fraction of loci comprising enhancer predictions was defined as the number of loci in which at least one of the scanned sequences was considered an enhancer prediction divided by the total number of loci to which we applied the classifier. Therefore, the fold enrichments in Table [1](#T1){ref-type="table"} and Additional file [3](#S3){ref-type="supplementary-material"} were computed as the ratio of two ratios: (i) the total number of loci of highly expressed genes comprising at least one enhancer prediction each divided by the total number of loci of highly expressed genes comprising at least one scanned sequence each; and (ii) the total number of loci of lowly expressed genes comprising at least one enhancer prediction each divided by the total number of loci of lowly expressed genes comprising at least one scanned sequence each. Each of the latter ratios ranges between 0 (no loci comprising enhancer predictions) and 1 (all loci comprising scanned sequences also comprise enhancer predictions). For the 73 tissues evaluated and focusing only on CNEs across the human and mouse genomes, 59% of the loci of highly expressed genes comprised at least one enhancer prediction, while 52% of the loci of lowly expressed genes did.

### Overlap between predictions and different enhancer marks

Predictions resulting from the 73 reliable promoter-based classifiers were combined into a set of non-redundant predictions and overlapped with different enhancer marks. Additionally, when specifically stated, we report overlaps with predictions for particular promoter-based classifiers - for example, the classifier trained on liver promoters.

#### Overlap with p300

Genomic regions enriched for p300 in mouse forebrain, midbrain, limb, and heart tissues were extracted from Additional files [3](#S3){ref-type="supplementary-material"}, [4](#S4){ref-type="supplementary-material"} and [5](#S5){ref-type="supplementary-material"}\[[@B45]\], and mapped to the human genome (hg18) using LiftOver \[[@B106]\]. Genomic regions identified in forebrain, midbrain, limb, and heart were combined into one dataset. Overlapping genomic regions were clustered together.

#### Overlap with DNase I hypersensitivity sites

DNase I hypersensitivity data (\'narrow peaks\') for 86 human cell lines from the ENCODE project \[[@B25],[@B107]\] were downloaded from the UCSC browser \[[@B108],[@B109]\], converted to the hg18 assembly using LiftOver \[[@B106]\], and combined into one dataset. Overlapping genomic regions were clustered together. This resulted in a total of 1,722,559 non-overlapping regions with an average length of 253 bp. We then computed the intersection between the set of non-redundant enhancer predictions identified by any of the 73 promoter-based models and this DNase I hypersensitivity data dataset. Liver enhancer predictions, in particular, were also compared with DNase I hypersensitivity data in HepG2. Predictions for enhancers in other tissues were compared with DNase I hypersensitivity data in closely related ENCODE tissues and cell lines (Figure S9 in Additional file [1](#S1){ref-type="supplementary-material"}).

#### Overlap with histone modification marks

Histone mark data (H3K4me1, H3K27ac) for 11 human cell lines from the ENCODE project \[[@B25],[@B107]\] were downloaded from the UCSC browser \[[@B108],[@B110]\], converted to the hg18 assembly using LiftOver \[[@B106]\], and combined into one dataset. Overlapping genomic regions were clustered together. This resulted in a total of 189,889 non-overlapping regions with an average length of 6,275 bp. We then computed the intersection between the set of non-redundant enhancer predictions identified by any of the 73 promoter-based models and this histone mark dataset. Liver enhancer predictions, in particular, were also compared with histone marks in HepG2.

#### Overlap with ChromHMM predictions

Weak and strong enhancers identified in nine human cell lines (HSMM, GM12878, HUVEC, H1-hESC, K562, HepG2, NHEK, HMEC, NHLF) using ChromHMM \[[@B51]\] were downloaded from the UCSC browser \[[@B108],[@B111]\], converted to the hg18 assembly using LiftOver \[[@B106]\], and combined into one dataset. Overlapping genomic regions were clustered together. This resulted in a total of 399,500 non-overlapping regions with an average length of 1,504 bp. We then computed the intersection between the set of non-redundant enhancer predictions identified by any of the 73 promoter-based models and the ChromHMM dataset. Liver enhancer predictions, in particular, were also compared with ChromHMM enhancers in HepG2.

### Conservation analysis

PhastCons conservation scores \[[@B56]\] were based on alignment of 28 vertebrate species and an 18 species placental mammal subset, respectively \[[@B55]\].

### In vivo validation *of liver enhancer predictions*

Sequences selected for *in vivo* validation were PCR-amplified using TopTaq (Qiagen, Hilden, Germany) from human genomic DNA (Roche, Basel, Switzerland), purified using the QIAquick PCR purification kit (Qiagen) and cloned into the pENTR-dTOPO vector (Life Technologies, Carlsbad, CA, USA). Proper insertion and orientation was confirmed by colony PCR, after which positive clones were transferred into the pGL4.23\[luc2\] vector (Promega) using the Gateway system (Life Technologies). Sequence and orientation of the insert were re-verified by Sanger sequencing, and approximately 200 μg of endotoxin-free plasmid DNA was isolated using the EndoFree Plasmid Midi prep (Qiagen).

For the hydrodynamic tail vein assay, 10 μg of each assayed sequence in pGL4.23\[luc2\] was injected along with 2 μg of pGL4.74\[hRluc/TK\] vector to correct for injection efficiency, into at least three CD1 mice (Charles River Laboratories, Wilmington, MA, USA) using the TransIT EE hydrodynamic gene delivery system (Mirus Bio LCC, Madison, WI, USA) according to the manufacturer's protocol. Negative (empty pGL4.23\[luc2\]) and positive (*ApoE* liver enhancer \[[@B110],[@B112]\]) controls (n = 3 to 5) were also injected at each injection date/experiment. After 24 hours, livers were harvested and homogenized in passive lysis buffer (Promega), followed by centrifugation at 4°C for 30 minutes at 14,000 rpm. Firefly and Renilla luciferase activity in the supernatant (diluted 1:20) were measured on a Synergy 2 microplate reader (BioTek Instruments, Winooski, VT, USA) in technical replicates of four for each liver, using the Dual-Luciferase reporter assay system (Promega). The ratios for firefly luciferase:Renilla luciferase were determined and expressed as relative luciferase activity. All mouse work was approved by the UCSF Institutional Animal Care and Use Committee.
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